Adiponectin through its biphasic serum level is a useful biomarker during transition from diastolic dysfunction to systolic dysfunction - An experimental study

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Fu, Mingqiang ^a   Zhou, Jingmin ^a   Qian, Juying ^a   Jin, Xuejuan ^a   Zhu, Hongmin ^a   Zhong, Chunlin ^a   Fu, Michael ^b   Zou, Yunzeng ^a   Ge, Junbo ^a  

^a FUDAN UNIVERSITY   (China)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adiponectin; Biomarker; Diastolic function; Hypertension; Systolic function

Indexed keywords

ADIPONECTIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; INTERLEUKIN 6;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART INDEX; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HYPERTENSION; INFLAMMATION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; SYSTOLIC DYSFUNCTION;

ADIPONECTIN; ANIMALS; BASE SEQUENCE; BIOLOGICAL MARKERS; DIASTOLE; DISEASE PROGRESSION; GENE EXPRESSION; HEART FAILURE; HYPERTENSION; INTERLEUKIN-6; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RATS; RATS, INBRED SHR; RNA, MESSENGER; SYSTOLE;

RATTUS;

EID: 84865479831     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-106     Document Type: Article

References (38)

1. Adipose tissue, inflammation and cardiovascular disease. Ikeoka D, Mader JK, Pieber TR, Rev Assoc Med Bras 2010 56 116 121 10.1590/S0104- 42302010000100026 20339797
2. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB, Nature 2005 436 356 362 10.1038/nature03711 16034410 (Pubitemid 41065039)
3. Obesity, inflammation, and vascular disease: the role of the adipose tissue as an endocrine organ. Calabro P, Yeh ET, Subcell Biochem 2007 42 63 91 10.1007/1-4020-5688-5-3 17612046
4. Adipose tissue: from lipid storage compartment to endocrine organ. Scherer PE, Diabetes 2006 55 1537 1545 10.2337/db06-0263 16731815 (Pubitemid 44324105)
5. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y, Biochem Biophys Res Commun 1999 257 79 83 10.1006/bbrc.1999.0255 10092513 (Pubitemid 29299050)
6. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K, Biochem Biophys Res Commun 1996 221 286 289 10.1006/bbrc.1996.0587 8619847 (Pubitemid 26136463)
7. The adiponectin signaling pathway as a novel pharmacological target. Mao X, Hong JY, Dong LQ, Mini Rev Med Chem 2006 6 1331 1340 10.2174/ 138955706778992978 17168809 (Pubitemid 44890540)
8. Adiponectin-mediated modulation of hypertrophic signals in the heart. Shibata R, Ouchi N, Ito M, Kihara S, Shiojima I, Pimentel DR, Kumada M, Sato K, Schiekofer S, Ohashi K, Funahashi T, Colucci WS, Walsh K, Nat Med 2004 10 1384 1389 10.1038/nm1137 15558058 (Pubitemid 40022722)
9. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y, Nat Med 2002 8 731 737 10.1038/nm724 12068289 (Pubitemid 34778727)
10. Adiponectin and adiponectin receptors. Kadowaki T, Yamauchi T, Endocr Rev 2005 26 439 451 10.1210/er.2005-0005 15897298 (Pubitemid 40686653)
11. Adiponectin and cardiovascular disease: state of the art? Szmitko PE, Teoh H, Stewart DJ, Verma S, Am J Physiol Heart Circ Physiol 2007 292 1655 H1663 17142348
12. Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M, Metabolism 2006 55 478 488 10.1016/j.metabol.2005.10.009 16546478
13. Adiponectin levels associated with the development of hypertension: a prospective study. Imatoh T, Miyazaki M, Momose Y, Tanihara S, Une H, Hypertens Res 2008 31 229 233 10.1291/hypres.31.229 18360041 (Pubitemid 351461101)
14. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Chow WS, Cheung BM, Tso AW, Xu A, Wat NM, Fong CH, Ong LH, Tam S, Tan KC, Janus ED, Lam TH, Lam KS, Hypertension 2007 49 1455 1461 10.1161/HYPERTENSIONAHA.107.086835 17452504 (Pubitemid 46809394)
15. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Sahn DJ, DeMaria A, Kisslo J, Weyman A, Circulation 1978 58 1072 1083 10.1161/01.CIR.58.6.1072 709763 (Pubitemid 9091990)
16. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, Arce J, J Am Coll Cardiol 1987 10 733 742 10.1016/S0735-1097(87)80264-4 3655141 (Pubitemid 17163095)
17. Similarities of genetic (spontaneous) hypertension. Man and rat. Trippodo NC, Frohlich ED, Circ Res 1981 48 309 319 10.1161/01.RES.48.3.309 7460205 (Pubitemid 11102692)
18. The ageing spontaneously hypertensive rat as a model of the transition from stable compensated hypertrophy to heart failure. Boluyt MO, Bing OH, Lakatta EG, Eur Heart J 1995 16 19 30 8682057 (Pubitemid 26082317)
19. Echocardiographic measurement of left ventricular mass and volume in normotensive and hypertensive rats. Necropsy validation. de Simone G, Wallerson DC, Volpe M, Devereux RB, Am J Hypertens 1990 3 688 696 2222977 (Pubitemid 20330613)
20. Transthoracic echocardiography in models of cardiac disease in the mouse. Tanaka N, Dalton N, Mao L, Rockman HA, Peterson KL, Gottshall KR, Hunter JJ, Chien KR, Ross J Jr, Circulation 1996 94 1109 1117 10.1161/01.CIR.94.5.1109 8790053 (Pubitemid 26292868)
21. Effects of anesthesia on diastolic function in mice assessed by echocardiography. Schaefer A, Meyer GP, Brand B, Hilfiker-Kleiner D, Drexler H, Klein G, Echocardiography 2005 22 665 670 10.1111/j.1540-8175.2005.40096.x 16174120 (Pubitemid 43942743)
22. Diagnosing primary diastolic heart failure. Brutsaert DL, Eur Heart J 2000 21 94 96 10.1053/euhj.1999.1669 10637079 (Pubitemid 30072620)
23. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi N, Hori M, Lim YJ, Mishima M, Masuyama T, J Am Coll Cardiol 2004 43 55 60 10.1016/j.jacc.2003.07.037 14715184 (Pubitemid 38045916)
24. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA, Breathing Not Properly Multinational Study Investigators, J Am Coll Cardiol 2003 41 2010 2017 10.1016/S0735-1097(03)00405-4 12798574 (Pubitemid 36677124)
25. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. Troughton RW, Prior DL, Pereira JJ, Martin M, Fogarty A, Morehead A, Yandle TG, Richards AM, Starling RC, Young JB, Thomas JD, Klein AL, J Am Coll Cardiol 2004 43 416 422 10.1016/j.jacc.2003.08.046 15013124 (Pubitemid 38167702)
26. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Mottram PM, Leano R, Marwick TH, Am J Cardiol 2003 92 1434 1438 10.1016/j.amjcard.2003. 08.053 14675580 (Pubitemid 37532566)
27. The risk of cardiovascular death in elderly patients with possible heart failure. Results from a 6-year follow-up of a Swedish primary care population. Alehagen U, Lindstedt G, Levin LA, Dahlström U, Int J Cardiol 2005 100 17 27 10.1016/j.ijcard.2004.03.031 15820281 (Pubitemid 40487932)
28. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM, Blood Press 2004 13 236 242 10.1080/08037050410021397 15581338 (Pubitemid 39248187)
29. Circulating adiponectin concentrations in patients with congestive heart failure. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, Grossman E, Sheps D, Keren G, Roth A, Heart 2006 92 1420 1424 10.1136/hrt.2005.083345 16621874 (Pubitemid 44578832)
30. Evaluation of serum adiponectin levels in patients with heart failure and relationship with functional capacity. Oztürk M, Dursunolu D, Göksoy H, Rota S, Gür S, Turk Kardiyol Dern Ars 2009 37 384 390 20019451
31. A novel serum protein similar to C1q, produced exclusively in adipocytes. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF, J Biol Chem 1995 270 26746 26749 10.1074/jbc.270.45.26746 7592907
32. Relationship of serum adiponectin and leptin concentrations with body fat distribution in humans. Staiger H, Tschritter O, Machann J, Thamer C, Fritsche A, Maerker E, Schick F, Häring HU, Stumvoll M, Obes Res 2003 11 368 372 10.1038/oby.2003.48 12634431 (Pubitemid 41151622)
33. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Fisher FM, McTernan PG, Valsamakis G, Chetty R, Harte AL, Anwar AJ, Starcynski J, Crocker J, Barnett AH, McTernan CL, Kumar S, Horm Metab Res 2002 34 650 654 10.1055/s-2002-38246 12660876 (Pubitemid 36398701)
34. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y, J Am Soc Nephrol 2002 13 134 141 11752030 (Pubitemid 34042020)
35. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Tietge UJ, Böker KH, Manns MP, Bahr MJ, Am J Physiol Endocrinol Metab 2004 287 82 E89 10.1152/ajpendo.00494.2003 15010338 (Pubitemid 38856286)
36. Human fat cell lipolysis: biochemistry, regulation and clinical role. Arner P, Best Pract Res Clin Endocrinol Metab 2005 19 471 482 10.1016/j.beem.2005.07.004 16311212 (Pubitemid 41819214)
37. Pathophysiological significance of adiponectin. Nishida M, Funahashi T, Shimomura I, Med Mol Morphol 2007 40 55 67 10.1007/s00795-007-0366-7 17572841 (Pubitemid 47305235)
38. Relationship between adipocyte size and adipokine expression and secretion. Skurk T, Alberti-Huber C, Herder C, Hauner H, J Clin Endocrinol Metab 2007 92 1023 1033 17164304 (Pubitemid 46465679)